EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Angiotensin-converting enzyme inhibition and Na appetite: microbehavioral analysis and nycthemeral physiology



Angiotensin-converting enzyme inhibition and Na appetite: microbehavioral analysis and nycthemeral physiology



American Journal of Physiology 265(1 Pt 2): R7-13



The present experiments describe a marked nycthemeral rhythm in both the appetite for 0.3 M NaCl solution and components of the renin-angiotensin-aldosterone axis stimulated in Sprague-Dawley rats by chronic administration of enalapril, an angiotensin I-converting enzyme inhibitor. Continuous recording of water, NaCl, and food intakes shows that the sodium appetite is manifest as discrete bouts of salt ingestion in temporal proximity to meals and is partially independent of water bouts. In particular, salt bouts occur without water bouts in the late afternoon of a 12:12-h light-dark cycle and continue periprandially with water bouts during the night. Intake of all three commodities is minimal in the morning. In a second experiment, it was determined that plasma renin activity (PRA) was maximally elevated by chronic enalapril in the daytime and that plasma aldosterone was reduced by enalapril but continued to show nycthemeral rhythm peaking in the afternoon. The concurrent maxima in PRA and aldosterone in the afternoon in enalapril-treated rats thus coincides with NaCl intake in the absence of water intake. Reprinted by permission of the publisher. .

(PDF emailed within 1 workday: $29.90)

Accession: 002301430

Download citation: RISBibTeXText

PMID: 8342700



Related references

Angiotensin-converting enzyme inhibition and sodium appetite: Microbehavioral analysis and nycthemeral physiology. American Journal of Physiology 265(1 PART 2): R7-R13, 1993

Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation. Shock 43(4): 395-404, 2016

Murine Recombinant Angiotensin-Converting Enzyme 2 Effect on Angiotensin II-Dependent Hypertension and Distinctive Angiotensin-Converting Enzyme 2 Inhibitor Characteristics on Rodent and Human Angiotensin-Converting Enzyme 2 Renin-Angiotensin-Aldosteron. 2012

Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats. American Journal of Hypertension 16(11 Pt 1): 931-937, 2003

Placebo-controlled, randomised, angiotensin converting enzyme inhibition, comparative trial in cardiac infarction and left ventricular function Benefits of immediate angiotensin converting enzyme inhibition Results of the practical study. European Heart Journal 14(ABSTR SUPPL ): 432, 1993

Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: Relationship to angiotensin-converting enzyme inhibition. European Journal of Clinical Pharmacology 46(5): 431-436, 1994

Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats. Journal of Biochemical and Molecular Toxicology 27(7): 378-387, 2013

Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension 43(4): 854-859, 2004

Discrepancy between first dose angiotensin converting enzyme inhibition at rest and subsequent angiotensin converting enzyme inhibition during exercise in heart failure. Journal Of The American College Of Cardiologyuppl. A: 70a, 1986

Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clinical Pharmacology and Therapeutics 65(4): 448-459, 1999

Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. Journal of Pharmacology and Experimental Therapeutics 284(3): 1180-1187, 1998

Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension 60(3): 730-740, 2013

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Annals of Internal Medicine 127(5): 337-345, 1997

Inhibition of angiotensin converting enzyme by 10 desleucine angiotensin i a potential mechanism of endogenous angiotensin converting enzyme regulation. Biochimica et Biophysica Acta 871(1): 1-5, 1986